DBV Technologies S.A.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel Tassé
- Full Time Employees
- 161
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 177-181 Avenue Pierre Brossolette Montrouge France 92120
- IPO Date
- Oct 22, 2014
- CIK
- 0001613780
- Website
- dbv-technologies.com
- Similar Companies
- Business
- DBV Technologies S.A. DBV Technologies S.A. is a clinical-stage biopharmaceutical company that develops epicutaneous immunotherapy (EPIT) products via its proprietary Viaskin patch technology, which delivers allergens through intact skin to treat food allergies and immunological diseases; core pipeline assets include Viaskin Peanut (DBV712) for peanut allergy with ongoing Phase 3 and long-term studies in children aged 1-7 years, Viaskin Milk (DBV135) for cow's milk allergy following completion of a Phase 1/2 trial in pediatric and adolescent patients, and Viaskin Milk for cow's milk-induced eosinophilic esophagitis (EoE) after a completed Phase 2a study sponsored by the Children's Hospital of Philadelphia. The company, founded in 2002 and headquartered in Châtillon, France, with North American operations in Warren, New Jersey, targets pediatric and adolescent patients with severe food allergies such as peanut and milk, operating primarily in Europe and North America through research, clinical development, and regulatory pathways including planned Biologics License Application submission to the U.S. FDA for Viaskin Peanut in children aged 4-7 years. Recent developments encompass a March 2025 financing of up to $306.9 million to support Viaskin Peanut advancement through BLA submission and potential commercial launch, an October 2025 at-the-market sale of approximately $30 million in American Depositary Shares to extend cash runway into late 2026, alignment with the FDA on safety data requirements for the Viaskin Peanut BLA in younger children, and increased investments from entities including Braidwell LP in September 2024.
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript
DBV Technologies Q2 Earnings Call Highlights
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies Announces the Results of its 2026 Combined General Meeting
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
Combined General Meeting of June 3, 2026
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
DBV Technologies Reports First Quarter 2026 Financial Results
Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?